176 related articles for article (PubMed ID: 33567990)
1. Expression, Activity, and Regulation of Phosphorylating Enzymes in Tissues and Cells Relevant to HIV-1 Sexual Transmission.
Hu M; Valicherla GR; Zhou T; Hillier SL; Rohan LC
AIDS Res Hum Retroviruses; 2022 Jan; 38(1):22-32. PubMed ID: 33567990
[TBL] [Abstract][Full Text] [Related]
2. Depot Medroxyprogesterone Acetate and the Vaginal Microbiome as Modifiers of Tenofovir Diphosphate and Lamivudine Triphosphate Concentrations in the Female Genital Tract of Ugandan Women: Implications for Tenofovir Disoproxil Fumarate/Lamivudine in Preexposure Prophylaxis.
Nicol MR; Eneh P; Nakalega R; Kaiser T; Kabwigu S; Isingel E; Beksinska M; Sykes C; Fowler MG; Brown TT; Staley C; Kiweewa Matovu F
Clin Infect Dis; 2020 Apr; 70(8):1717-1724. PubMed ID: 31131846
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Genetic Variants of the Kinases That Activate Tenofovir in a Compartment-specific Manner.
Lade JM; To EE; Hendrix CW; Bumpus NN
EBioMedicine; 2015 Sep; 2(9):1145-52. PubMed ID: 26501112
[TBL] [Abstract][Full Text] [Related]
4. Hormonal Contraceptives Differentially Suppress TFV and TAF Inhibition of HIV Infection and TFV-DP in Blood and Genital Tract CD4+ T cells.
Shen Z; Rodriguez-Garcia M; Patel MV; Bodwell J; Kashuba ADM; Wira CR
Sci Rep; 2017 Dec; 7(1):17697. PubMed ID: 29255206
[TBL] [Abstract][Full Text] [Related]
5. The effect of depot medroxyprogesterone acetate on tenofovir alafenamide in rhesus macaques.
Daly MB; Sterling M; Holder A; Dinh C; Nishiura K; Khalil G; García-Lerma JG; Dobard C
Antiviral Res; 2021 Feb; 186():105001. PubMed ID: 33385420
[TBL] [Abstract][Full Text] [Related]
6. Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue.
Dobard C; Sharma S; Martin A; Pau CP; Holder A; Kuklenyik Z; Lipscomb J; Hanson DL; Smith J; Novembre FJ; García-Lerma JG; Heneine W
J Virol; 2012 Jan; 86(2):718-25. PubMed ID: 22072766
[TBL] [Abstract][Full Text] [Related]
7. Seminal Tenofovir Concentrations, Viral Suppression, and Semen Quality With Tenofovir Alafenamide, Compared With Tenofovir Disoproxil Fumarate (Spanish HIV/AIDS Research Network, PreEC/RIS 40).
Imaz A; Niubó J; Cottrell ML; Perez E; Kashuba ADM; Tiraboschi JM; Morenilla S; Garcia B; Podzamczer D
Clin Infect Dis; 2019 Sep; 69(8):1403-1409. PubMed ID: 30561517
[TBL] [Abstract][Full Text] [Related]
8. Tenofovir alafenamide (TAF) does not deplete mitochondrial DNA in human T-cell lines at intracellular concentrations exceeding clinically relevant drug exposures.
Stray KM; Park Y; Babusis D; Callebaut C; Cihlar T; Ray AS; Perron M
Antiviral Res; 2017 Apr; 140():116-120. PubMed ID: 28131805
[TBL] [Abstract][Full Text] [Related]
9. Sex hormones regulate tenofovir-diphosphate in female reproductive tract cells in culture.
Shen Z; Fahey JV; Bodwell JE; Rodriguez-Garcia M; Kashuba AD; Wira CR
PLoS One; 2014; 9(6):e100863. PubMed ID: 24978212
[TBL] [Abstract][Full Text] [Related]
10. Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors.
García-Lerma JG; Aung W; Cong ME; Zheng Q; Youngpairoj AS; Mitchell J; Holder A; Martin A; Kuklenyik S; Luo W; Lin CY; Hanson DL; Kersh E; Pau CP; Ray AS; Rooney JF; Lee WA; Heneine W
J Virol; 2011 Jul; 85(13):6610-7. PubMed ID: 21525346
[TBL] [Abstract][Full Text] [Related]
11. Effects of tenofovir on cytokines and nucleotidases in HIV-1 target cells and the mucosal tissue environment in the female reproductive tract.
Biswas N; Rodriguez-Garcia M; Shen Z; Crist SG; Bodwell JE; Fahey JV; Wira CR
Antimicrob Agents Chemother; 2014 Nov; 58(11):6444-53. PubMed ID: 25136003
[TBL] [Abstract][Full Text] [Related]
12. Vaginal Microbiota and Mucosal Pharmacokinetics of Tenofovir in Healthy Women Using a 90-Day Tenofovir/Levonorgestrel Vaginal Ring.
Thurman AR; Ravel J; Gajer P; Marzinke MA; Ouattara LA; Jacot T; Peet MM; Clark MR; Doncel GF
Front Cell Infect Microbiol; 2022; 12():799501. PubMed ID: 35350436
[TBL] [Abstract][Full Text] [Related]
13. Antiviral Activity of Tenofovir Alafenamide against HIV-1 with Thymidine Analog-Associated Mutations and M184V.
Margot N; Ram R; Abram M; Haubrich R; Callebaut C
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31988104
[TBL] [Abstract][Full Text] [Related]
14. Differential Mechanisms of Tenofovir and Tenofovir Disoproxil Fumarate Cellular Transport and Implications for Topical Preexposure Prophylaxis.
Taneva E; Crooker K; Park SH; Su JT; Ott A; Cheshenko N; Szleifer I; Kiser PF; Frank B; Mesquita PM; Herold BC
Antimicrob Agents Chemother; 2015 Dec; 60(3):1667-75. PubMed ID: 26711762
[TBL] [Abstract][Full Text] [Related]
15. Naturally Occurring Mutations to Muscle-Type Creatine Kinase Impact Its Canonical and Pharmacological Activities in a Substrate-Dependent Manner In Vitro.
Mosher EP; Eberhard CD; Bumpus NN
Mol Pharmacol; 2021 Dec; 100(6):588-596. PubMed ID: 34561299
[TBL] [Abstract][Full Text] [Related]
16. Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
Lanier ER; Ptak RG; Lampert BM; Keilholz L; Hartman T; Buckheit RW; Mankowski MK; Osterling MC; Almond MR; Painter GR
Antimicrob Agents Chemother; 2010 Jul; 54(7):2901-9. PubMed ID: 20439609
[TBL] [Abstract][Full Text] [Related]
17. Nucleoside Triphosphate Diphosphohydrolase 1 Exhibits Enzymatic Activity toward Tenofovir Diphosphate.
Seneviratne HK
Drug Metab Dispos; 2023 Mar; 51(3):385-391. PubMed ID: 36396461
[TBL] [Abstract][Full Text] [Related]
18. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission.
Patterson KB; Prince HA; Kraft E; Jenkins AJ; Shaheen NJ; Rooney JF; Cohen MS; Kashuba AD
Sci Transl Med; 2011 Dec; 3(112):112re4. PubMed ID: 22158861
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of topical tenofovir against transmission of a tenofovir-resistant SHIV in macaques.
Dobard CW; Sharma S; Cong ME; West R; Makarova N; Holder A; Pau CP; Hanson DL; Novembre FJ; Garcia-Lerma JG; Heneine W
Retrovirology; 2015 Aug; 12():69. PubMed ID: 26253002
[TBL] [Abstract][Full Text] [Related]
20. Predicting Pharmacokinetics of a Tenofovir Alafenamide Subcutaneous Implant Using Physiologically Based Pharmacokinetic Modelling.
Rajoli RKR; Demkovich ZR; Flexner C; Owen A; Siccardi M
Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32423957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
